UTHR Q1 2022 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$462M+21.8% YoY

Gross Profit

$436M94.4% margin

Operating Income

$288M62.4% margin

Net Income

$240M51.9% margin

EPS (Diluted)

$5.03

QoQ Revenue Growth

+11.2%

Cash Flow

Operating Cash Flow

$289M

Free Cash Flow

$275M

Stock-Based Comp.

-$21M

Balance Sheet

Total Assets

$5.4B

Total Liabilities

$1.2B

Stockholders' Equity

$4.2B

Cash & Equivalents

$813M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$462M	$379M	+21.8%
Gross Profit	$436M	$356M	+22.4%
Operating Income	$288M	-$65M	+544.4%
Net Income	$240M	$28M	+747.7%

Revenue Segments

Tyvaso

$172M38%

Remodulin

$132M29%

Orenitram

$83M18%

Unituxin

$56M12%

Adcirca

$10M2%

Geographic Segments

UNITED STATES

$410M89%

Non-US

$52M11%